Published in Semin Liver Dis on August 01, 2001
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
Liver cirrhosis. Lancet (2008) 6.11
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal (2008) 1.60
Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem (2010) 1.58
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol (2007) 1.22
Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol (2005) 1.21
Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet (2011) 1.20
Molecular serum markers of liver fibrosis. Biomark Insights (2012) 1.20
MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay. PLoS One (2011) 1.19
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 1.15
Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med (2010) 1.13
Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut (2005) 1.13
Connective tissue growth factor with a novel fibronectin binding site promotes cell adhesion and migration during rat oval cell activation. Hepatology (2008) 1.12
Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am J Pathol (2010) 1.11
Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol (2011) 1.06
Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair (2010) 1.05
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01
Molecular therapy for hepatic injury and fibrosis: where are we? World J Gastroenterol (2006) 1.01
Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res (2012) 1.00
Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int (2011) 1.00
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
The lens as a model for fibrotic disease. Philos Trans R Soc Lond B Biol Sci (2011) 0.97
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2015) 0.97
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol (2014) 0.97
Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) (2012) 0.96
Inhibitive effect of cordyceps sinensis on experimental hepatic fibrosis and its possible mechanism. World J Gastroenterol (2003) 0.95
Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol (2011) 0.94
Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res (2012) 0.93
The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res (2013) 0.93
Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Dig Dis Sci (2010) 0.93
Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair (2010) 0.92
Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol (2004) 0.91
Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells. Int J Mol Sci (2011) 0.89
Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells. Fibrogenesis Tissue Repair (2009) 0.89
Antioxidants vitamin E and C attenuate hepatic fibrosis in biliary-obstructed rats. World J Gastroenterol (2006) 0.89
In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell (2016) 0.88
Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease. J Korean Med Sci (2009) 0.87
Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol (2015) 0.87
Role of host genetics in fibrosis. Fibrogenesis Tissue Repair (2009) 0.86
Proteomic analysis of naturally-sourced biological scaffolds. Biomaterials (2015) 0.86
Matrix Metalloproteinase Mediated Type I Collagen Degradation - An Independent Risk Factor for Mortality in Women. EBioMedicine (2015) 0.86
Complement 5a stimulates hepatic stellate cells in vitro, and is increased in the plasma of patients with chronic hepatitis B. Immunology (2013) 0.85
Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology (2015) 0.85
Efficient hepatic delivery of drugs: novel strategies and their significance. Biomed Res Int (2013) 0.85
Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther (2013) 0.85
Lysyl oxidase: a potential target for cancer therapy. Inflammopharmacology (2010) 0.84
In vivo effects of Chinese herbal recipe, Danshaohuaxian, on apoptosis and proliferation of hepatic stellate cells in hepatic fibrotic rats. World J Gastroenterol (2005) 0.83
The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci (2007) 0.82
Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo. World J Gastroenterol (2005) 0.82
Effect of Astragalus complanatus flavonoid on anti-liver fibrosis in rats. World J Gastroenterol (2005) 0.81
Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model. BMC Res Notes (2012) 0.81
A Multiscale Agent-Based in silico Model of Liver Fibrosis Progression. Front Bioeng Biotechnol (2014) 0.81
Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Res Ther (2016) 0.81
Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models. World J Gastroenterol (2006) 0.80
Characterization of Decellularized Heart Matrices as Biomaterials for Regular and Whole Organ Tissue Engineering and Initial In-vitro Recellularization with Ips Cells. J Tissue Sci Eng (2012) 0.80
Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes. Clin Exp Immunol (2009) 0.80
Human liver myofibroblasts during development and diseases with a focus on portal (myo)fibroblasts. Front Physiol (2015) 0.79
Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker development. Am J Transl Res (2013) 0.79
Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury. Biomed Res Int (2016) 0.78
Effects of vitamins E and C supplementation on hepatic glutathione peroxidase activity and tissue injury associated with ethanol ingestion in malnourished rats. Curr Ther Res Clin Exp (2006) 0.78
Potential Role of the Gut/Liver/Lung Axis in Alcohol-Induced Tissue Pathology. Biomolecules (2015) 0.78
Mediators leading to fibrosis - how to measure and control them in tissue engineering. Oper Tech Orthop (2010) 0.78
Recellularization of rat liver scaffolds by human liver stem cells. Tissue Eng Part A (2015) 0.76
Rhus verniciflua Stokes attenuates cholestatic liver cirrhosis-induced interstitial fibrosis via Smad3 down-regulation and Smad7 up-regulation. Anat Cell Biol (2016) 0.75
Biomarkers of disease differentiation: HCV recurrence versus acute cellular rejection. Fibrogenesis Tissue Repair (2012) 0.75
Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are? World J Gastroenterol (2014) 0.75
Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci (2014) 0.75
A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. World J Gastroenterol (2006) 0.75
Targeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver Fibrosis. Front Pharmacol (2016) 0.75
Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Collapsed Reticular Network and its Possible Mechanism during the Initiation and/or Progression of Hepatic Fibrosis. Sci Rep (2016) 0.75
Fistulising Crohn's disease: MMPs gone awry. Gut (2004) 0.75
Expression of tissue inhibitor of matrix metalloproteinases-1 during aging in rat liver. World J Gastroenterol (2005) 0.75
Neo-Epitopes-Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis. PLoS One (2016) 0.75
New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis (2016) 0.75
Circulating levels of a collagen type v propeptide fragment in a carbon tetrachloride reversible model of liver fibrosis. Biomark Insights (2012) 0.75
Increased serum activity of matrix metalloproteinase-9 in patients with acute variceal bleeding. Gut Liver (2012) 0.75
Rapid production of human liver scaffolds for functional tissue engineering by high shear stress oscillation-decellularization. Sci Rep (2017) 0.75
Effect of leflunomide on liver regeneration after partial hepatectomy in rats. Pediatr Surg Int (2010) 0.75
1,4-Butanediol diglycidyl ether-cross-linked hyaluronan inhibits fibrosis in rat primary tenocytes by down-regulating autophagy modulation. J Mater Sci Mater Med (2016) 0.75
Curative in situ ablation of colorectal liver metastases-experimental and clinical implementation. Int J Colorectal Dis (2006) 0.75
Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology (1999) 2.71
In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology (1989) 2.34
Successful treatment of Bouveret's syndrome by endoscopic laserlithotripsy. Endoscopy (1999) 2.00
Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology (1998) 1.92
Tele-endoscopy: influence of data compression, bandwidth and simulated impairments on the usability of real-time digital video endoscopy transmissions for medical diagnoses. Endoscopy (2002) 1.89
Women encounter ADRs more often than do men. Eur J Clin Pharmacol (2008) 1.83
Benefits and risks of needle-knife papillotomy. Gastrointest Endosc (1997) 1.80
Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun (1998) 1.67
Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut (1998) 1.67
The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology (1989) 1.60
An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology (2000) 1.60
Prevalence of Helicobacter pylori infection in coronary artery disease and effect of its eradication on coronary lumen reduction after percutaneous coronary angioplasty. Dig Liver Dis (2001) 1.59
Hepatitis C and liver fibrosis. Cell Death Differ (2003) 1.53
Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf (2000) 1.51
Correlation of polypoid lesions in the distal colorectum and proximal colon in asymptomatic screening subjects. Eur J Gastroenterol Hepatol (1996) 1.45
[Auto-CPAP treatment in obstructive sleep apnea syndrome: a prospective randomized study during initiation of treatment]. Dtsch Med Wochenschr (1997) 1.43
Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. Gut (2002) 1.43
Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med (2004) 1.42
Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J (2003) 1.41
[Decision to use complementary medicine: fact oriented or irrational?]. Dtsch Med Wochenschr (1996) 1.39
Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology (2001) 1.39
Disposable-sheath, flexible gastroscope system versus standard gastroscopes: a prospective, randomized trial. Gastrointest Endosc (1999) 1.38
Impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy techniques. Gastrointest Endosc (1999) 1.37
Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol (2001) 1.32
Management of difficult common bile duct stones. Gastrointest Endosc Clin N Am (2003) 1.31
Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. Eur Respir J (1998) 1.30
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut (2002) 1.29
KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc (1999) 1.28
Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine (2000) 1.27
Echo-enhanced color- and power-Doppler EUS for the discrimination between focal pancreatitis and pancreatic carcinoma. Gastrointest Endosc (2001) 1.26
Abdominal actinomycosis: complication of endoscopic stenting in chronic pancreatitis? Endoscopy (2001) 1.23
Risk of invasive carcinoma in colorectal adenomas assessed by size and site. Int J Colorectal Dis (1997) 1.21
Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Regul Pept (2004) 1.18
Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): a prospective randomized clinical trial. Endoscopy (1999) 1.18
Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol (1999) 1.14
Invasive carcinoma in colorectal adenomas: multivariate analysis of patient and adenoma characteristics. Endoscopy (1997) 1.14
Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J Biol Chem (1999) 1.14
Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol (2001) 1.14
Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis. Gut (1997) 1.13
Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer (2002) 1.12
Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol (2001) 1.12
Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Scand J Gastroenterol (1999) 1.10
Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol (2002) 1.10
Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology (1998) 1.10
Immunoglobulin E and eosinophilic cationic protein in segmental lavage fluid of the small and large bowel identify patients with food allergy. Am J Gastroenterol (2001) 1.09
Apoptosis in gastric mucosa with stress-induced gastric ulcers. J Physiol Pharmacol (1999) 1.08
[Comment on the contribution: "The diagnostic value of the amino acid absorption test in detection of disordered exocrine pancreas function" by Kemmer et al]. Z Gastroenterol (1993) 1.08
Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut (2000) 1.08
Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol (1995) 1.08
Celiac disease and its link to type 1 diabetes mellitus. J Pediatr Endocrinol Metab (2001) 1.07
Ghrelin-a new gastroprotective factor in gastric mucosa. J Physiol Pharmacol (2004) 1.07
Immunohistochemical distribution of collagens types IV, V, and VI and of pro-collagens types I and III in human alveolar bone and dentine. J Histochem Cytochem (1986) 1.07
Health-related quality of life in chronic pancreatitis: a psychometric assessment. Scand J Gastroenterol (2003) 1.07
Risk related surveillance following colorectal polypectomy. Gut (2002) 1.06
Undulin, an extracellular matrix glycoprotein associated with collagen fibrils. J Biol Chem (1990) 1.04
Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut (2002) 1.04
Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. Int J Cancer (1997) 1.03
Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci (2003) 1.03
Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J Physiol Pharmacol (2003) 1.03
Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol (2005) 1.03
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut (2005) 1.02
Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers. Eur J Pharmacol (2000) 1.02
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 1.01
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol (2005) 1.01
Isolation, culture, and characterization of human pancreatic duct cells. Pancreas (1993) 1.00
25 years of endoscopic sphincterotomy in Erlangen: assessment of the experience in 3498 patients. Endoscopy (1998) 0.99
Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver (2001) 0.99
Color doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist. J Clin Ultrasound (1996) 0.98
Changes in quality of life after medical intensive care. Intensive Care Med (2001) 0.98
Successful laserlithotripsy in Bouveret's syndrome using a new frequency doubled doublepulse Nd:YAG laser (FREDDY). Scand J Gastroenterol (2004) 0.98
Basement membrane components are potent promoters of rat intestinal epithelial cell differentiation in vitro. Gastroenterology (1990) 0.98
Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer. Int J Colorectal Dis (2001) 0.98
Coated and uncoated self-expanding metal stents for malignant stenosis in the upper GI tract: preliminary clinical experiences with Wallstents. Am J Gastroenterol (1994) 0.97
Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology (2003) 0.97
Post-ERCP pancreatitis: new momentum. Endoscopy (2002) 0.96
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol (2001) 0.96
Microscopic (collagenous and lymphocytic) colitis triggered by food allergy. Gut (2005) 0.96
Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res (2003) 0.95
Leptin modulates the inflammatory response in acute pancreatitis. Digestion (2002) 0.95
Increased prevalence of Helicobacter pylori infection in patients with celiac disease. Am J Gastroenterol (2000) 0.95
Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol (2003) 0.95
Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. J Intern Med (2002) 0.95
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech (2001) 0.95
Soluble collagen VI induces tyrosine phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase erk2 in fibroblasts. Exp Cell Res (1999) 0.95
Self-expanding metal stents for palliation of malignant obstruction in the upper gastrointestinal tract. Comparative assessment of three stent types implemented in 96 implantations. J Clin Gastroenterol (1996) 0.95
Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy (1999) 0.95
Induction of drought stress tolerance by ketoconazole in Catharanthus roseus is mediated by enhanced antioxidant potentials and secondary metabolite accumulation. Colloids Surf B Biointerfaces (2007) 0.94
[Fire-eater's lung. Two cases and review of the literature]. Dtsch Med Wochenschr (2006) 0.94
Fluorescence induced with 5-aminolevulinic acid for the endoscopic detection and follow-up of esophageal lesions. Gastrointest Endosc (2001) 0.94
Laser lithotripsy of difficult bile duct stones by means of a rhodamine-6G laser and an integrated automatic stone-tissue detection system. Gastrointest Endosc (1994) 0.94
Activation of genes for superoxide dismutase, interleukin-1beta, tumor necrosis factor-alpha, and intercellular adhesion molecule-1 during healing of ischemia-reperfusion-induced gastric injury. Scand J Gastroenterol (2000) 0.94
Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol (2000) 0.94
Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J Clin Ultrasound (2000) 0.93